This study enrolls adults who have tested positive for COVID-19 and are currently hospitalized. The purpose of this study is to learn whether giving donor plasma collected from patients who have recovered from COVID-19 infection to those who are having symptoms now helps with recovery.
You will be in this study for about 29-36 days. You will either get a convalescent plasma or a placebo (fluids with multivitamins) via IV infusion. Which you will get is random, like the flip of a coin. Neither you nor your doctor will know which you've been given. You will have regular blood draws while you are in the hospital and we will contact you by phone to check how you ware doing once you are discharged. This study takes place at Kaleida facilities in WNY.
Effective therapies for COVID-19 are urgently needed. Convalescent COVID-19donor plasma is the liquid part of blood that is collected from patients who haverecovered from COVID-19 infection. This plasma contains SARS-CoV-2 specificantibodies that may help patients with COVID-19 recover. Preliminary reportssuggest potential efficacy in small human studies. Clinical trial data are needed todetermine whether convalescent donor plasma is effective in treating COVID-19. This is a Multicenter, blinded, placebo-controlled randomized clinical trial
Adults ages 18+.
SARS-CoV-2 positive test within the past 14 days.
Currently hospitalized or in an emergency department with anticipated hospitalization.
Symptoms of acute respiratory infection.
Due to COVID-19, new enrollment in research studies will be greatly limited.
If you are interested in a study, there may be a longer waiting period to receive a response to your inquiry.
View the guidance for research participants for additional information.
Let us know how the study team can reach you.
If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email email@example.com and someone will assist you.